Shots:
- The conditional approval is based on the P-II L-MIND study evaluating the safety and efficacy of tafasitamab + lenalidomide in patients with r/r DLBCL who are not eligible for ASCT
- Results: ORR (56.8%); CR rate (39.5%); PR rate (17.3%) as assessed by an IRC; m-DoR (43.9mos.) after a minimum follow up of 35mos.
- Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting mAb & is co-marketed by both companies under the brand name Monjuvi in the US & Minjuvi in the EU. Additionally, both companies share global development rights for the therapy
Click here to read full press release/ article | Ref: Incyte | Image: Morphosys US
The post MorphoSys and Incyte’s Minjuvi (tafasitamab) + Lenalidomide Receive EC’s Approval for the Treatment of R/R DLBCL first appeared on PharmaShots.
